Commentary: Will 20th century patient safeguards be reversed in the 21st century?

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Gonsalves, Gregg ^a   Zuckerman, Diana ^b  

^a YALE UNIVERSITY   (United States)

^b National Center for Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; PRESCRIPTION DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVICE APPROVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; EXPERIMENTAL MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DEVICE; NOTE; PATIENT CARE; POLITICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED STATES; ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG DEVELOPMENT; HISTORY; HIV INFECTIONS; PATIENT SAFETY; STANDARDS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; PATIENT SAFETY; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84926384396     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1500     Document Type: Note

References (14)

1. Hilts PJ. Protecting America's health: the FDA, business, and one hundred years of regulation. Alfred A. Knopf, 2003.
2. Epstein S. Impure science: AIDS, activism, and the politics of knowledge. University of California Press, 1996.
3. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:S5-14.
4. Perrone M. Associated Press. AIDS activist takes up a new fight: defending FDA. 2014.www.focr.org/8-11-2014-associated-press-aids-activist-takes-new-fight-defending-fda.
5. Washburn J. Undue influence. The American Prospect 2001 Dec 19. http://prospect.org/ article/undue-influence.
6. Food and Drug Administration. Guidance for industry. Expedited programs for serious conditions-drugs and biologics. 2014. www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
7. Food and Drug Administration. How to apply for orphan drug designation. 2013. www. fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/ucm365086.htm.
8. Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration; the class of 2008. JAMA Intern Med 2014;174:90-5.
9. Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthrough-drug category-implications for patients. N Engl J Med 2014;370:1252-8.
10. US Government Accountability Office. Medical devices: FDA should take steps to ensure that high-risk device types are approved through the most stringent premarket review process. 2009. www.gao.gov/assets/290/284882.pdf.
11. Food and Drug Administration. Analysis of premarket review times under the 510(k) program. 2011. www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm263385.htm#a.
12. Food and Drug Administration. FDA proposes new expedited access program for medical devices that address unmet medical needs. 2014. www.fda.gov/newsevents/newsroom/ pressannouncements/ucm394294.htm.
13. Food and Drug Administration. Expedited access for premarket approval medical devices intended for unmet medical need for life threatening or irreversibly debilitating diseases or conditions-draft guidance for industry and Food and Drug Administration staff. 2014.www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ ucm393879.htm.
14. Energy and Commerce Committee of the US House of Representatives. 21st Century cures discussion draft. 2015. http://energycommerce.house.gov/sites/republicans. energycommerce.house.gov/files/114/Analysis/Cures/20150127-Cures-Discussion-Document.pdf.